UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13A-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of January 2019
COMMISSION FILE Number. 000-29338
CORREVIO PHARMA CORP.
(Translation of registrant’s name into English)
1441 Creekside Drive, 6th floor
Vancouver, British Columbia, V6J 4S7, CANADA
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
| Form 20-F ☒ | Form 40-F ☐ |
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
| Exhibit | Description | |
| 99.1 | Material Change Report Dated January 11, 2019 | |
Exhibit 99.1 of this report on Form 6-K is incorporated by reference into the Company’s registration statement on Form F-10 (File No. 333-225852) and registration statements on Form S-8 (File No. 333-199091 and File No. 333-199092).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CORREVIO PHARMA CORP. | ||
| (Registrant) | ||
| Date: January 11, 2019 | By: | /s/ Justin Renz |
| Name: Justin Renz | ||
| Title: Chief Financial Officer | ||
Exhibit 99.1
Form
51-102F3
MATERIAL CHANGE REPORT
Item 1 Name and
Address of Company
Correvio Pharma Corp. (“Correvio” or the “Company”)
1441 Creekside Dr.
6th floor
Vancouver, BC V6J 4S7
Item
2 Date of Material Change
January 1, 2019
Item
3 News Release
Correvio issued a news release with respect to the material change on January 2, 2019. The news release was disseminated via PR Newsire and subsequently filed on Correvio’s SEDAR profile.
Item 4 Summary of Material Change
On January 2, 2019, Correvio Pharma Corp. (“Correvio” or the “Company”) announced that Mark
H.N. Corrigan, MD, will be appointed as the Company’s new Chief Executive Officer by the end of the first quarter of 2019.
Correvio’s current President and Chief Executive Officer, William Hunter, MD, will transition out of his executive roles
but will retain his position as a member of the board of directors of the Company (the “Board”). The Company’s
current Chief Financial Officer, Justin Renz, has assumed the responsibilities of President of the Company, effective as of January
1, 2019. In addition, Vanda De Cian, MD, will join the Board effective as of March 12, 2019.
Item 5 Full Description of Material Change
5.1 Full Description of Material Change
On January 2, 2019, Correvio announced that Mark H.N. Corrigan, MD, will be appointed as the Company’s new Chief Executive Officer by the end of the first quarter of 2019. Dr. Corrigan is currently serving as a member of the Board. Correvio’s current President and Chief Executive Officer, William Hunter, MD, will transition out of his executive roles but will retain his position as a member of the Board. The Company’s current Chief Financial Officer, Justin Renz, has assumed the responsibilities of President of the Company effective January 1, 2019.
Vanda De Cian, MD, will join the Board, effective as of March 12, 2019. Dr. De Cian will serve as a member of both the Governance and Nominating Committee, and the Compensation Committee.
5.2 Disclosure for Restructuring Transactions
Not applicable.
Item 6 Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7 Omitted Information
Not applicable.
Item 8 Executive Officer
For further information, please contact:
Justin Renz
Chief Financial Officer
604-677-6905
Item 9 Date
of Report
January 11, 2019